Rare Diseases


Apremilast Reduces Oral Ulcers in Behçet’s Syndrome

January 28, 2020

Apremilast (Otezla, Celgene) resulted in a greater reduction in the number of oral ulcers associated with Behçet’s syndrome than placebo, say researchers recently writing in the New England Journal of Medicine.

New Treatment Option for Behçet’s Disease

July 22, 2019

On Friday, the U.S. Food and Drug  Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.

New Recommendations for Treatment of Paget’s Disease Released

March 07, 2019

A new set of treatment guidelines for Paget’s disease have been published leading with recommendations for the use of bisphosphonates.

How Much Do You Know About Behçet Disease?

November 28, 2018

Will you recognize Behçet disease when you see it?

Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis Gets FDA Nod

October 17, 2018

The approval is based on data from two randomized, sham injection-controlled, double-masked phase 3 clinical trials with patient follow-up for 3 years.

ACR 2018 Preview: A Look at What’s New in Rheumatology

October 16, 2018

Here: highlights of some of the studies that will be presented at the American College of Rheumatology 2018 Annual Meeting in Chicago from October 19 to 24.

FDA Approves First Drug for Eosinophilic Granulomatosis With Polyangiitis

December 21, 2017

Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.

Case Study: Devic’s Disease and Sjogren’s Syndrome

April 03, 2017

In this case study, Dr. Litvin presents a complicated case of neuromyelitis optica (Devic’s disease), a rare inflammatory autoimmune CNS disease affecting the spinal cord and optic nerves.

Uveitis Patient Selection Key for Adalimumab Treatment

September 28, 2016

Adalimumab for the treatment of noninfectious uveitis has advantages over no treatment or conventional treatment with steroid therapy.

Adalimumab Approved for Uveitis

July 07, 2016

In this story, we revisit the clinical trials that led to the approval of adalimumab for uveitis.

Adalimumab Improves Uveitis, Studies Show

November 16, 2015

Adalimumab improves function and quality of life for patients with uveitis, shows a study presented at 2015 ACR/ARHP.

Carbamylated Proteins as a Biomarker for Sjogren’s Syndrome

September 16, 2015

Autoantibodies against carbamylated proteins in Sjögren’s syndrome could be used as a new biomarker.

Abatacept Boosts Chances of Remission in Relapsing Granulomatosis

December 23, 2013

A small multicenter study shows that intravenous abatacept (Orencia) can produce a high rate of remission in patients with in non-severe relapsing Wegener’s granulomatosis with polyangiitis (GPA).

Options in Tough-To-Treat Uveitis

October 28, 2013

Reports in a pediatric ophthalmology journal reveal risk factors and best treatments for refractory/recurrent uveitis in JIA.

Granulomatosis With Polyangiitis, With Atypical Features

June 19, 2013

The manifestations of granulomatosis with polyangiitis varies widely. This case study describes a 49-year-old man who presented with cough, chills, and chest pain who had a mediastinal mass and ocular involvement.

Babesiosis in a Patient With Corticosteroid-Resistant Uveitis

August 29, 2012

The tumor necrosis factor α antagonist infliximab has been used for treating patients with uveitis resistant to corticosteroids.

Behçet syndrome: Taking a systemic approach

August 30, 2009

Behçet syndrome is a multisystem disease characterized by variable clinical manifestations. The diagnosis is based on recognition of a group of clinical features.